Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Deep endometriosis demystified: Natural progression, hormonal treatment, and malignant transformation
Green, Isabel C. , Stewart, Kelsey A, Stewart, Kelsey A. , Cope, Adela G. , Burnett, Tatnai L.

Current Opinion in Obstetrics & Gynecology | June 27, 2025 | Volume: 37 | Issue: 4 | Pages: 221-232

10.1097/gco.0000000000001036 | PMID 40304250 Get It

Purpose of review We present a review of the natural progression, response to hormonal therapy, and risk of malignancy associated with deep endometriosis (DE) to guide evidence-based discussion of conservative treatment. Recent findings Advanced imaging protocols have enhanced nonsurgical detection of DE, allowing noninvasive diagnosis, treatment, and surveillance. While some DE is progressive, 50% of disease appears stable over time, and progression is reduced by half with hormonal treatments (21 versus 12%). Hormonal treatment can reduce the size of DE lesions by 1 cm³, with reductions occurring after 6 months and remaining stable up to 3 years. Most hormonal therapies improve symptoms and quality of life, regardless of changes in DE size, with combined contraceptives and progestins being the most studied. DE may present a higher risk of ovarian and extraovarian cancer than previously hypothesized, though further research is needed to confirm findings. Limitations of DE research include differing imaging strategies, definitions of disease and progression, short follow-up, focus on rectosigmoid DE only, and lack of randomized trials. Summary DE is a subtype of endometriosis that is increasingly diagnosed and treated with noninvasive strategies. Hormonal treatments improve symptoms and reduce progression of DE. Further research on optimal conservative management and risk of malignancy is warranted.
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma
Breen, William G. , Anderson, S. Keith , Brown, Paul D. , Yan, Elizabeth , Kizilbash, Sani H. , Anderson, Daniel M. , Tran, David , Mazurczak, Miroslaw, Geoffroy, Francois J., Leinweber, Clinton, Dixon, Jesse G. , Anderson, S Keith , Yan, Elizabeth S, Kizilbash, Sani, Galanis, Eva, Kizilbash, Sani H , Sarkaria, Jann N. , Galanis, Evanthia , Tran, David D. , Johnson, Derek R. , Laack, Nadia N.

Neuro-Oncology | June 27, 2025 | Volume: 27 | Issue: 10 | Pages: 2661-2670

10.1093/neuonc/noaf156 | PMID 40579995 Get It

Abstract Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the maximum tolerated dose (MTD), safety, and efficacy of dasatinib with radiation and temozolomide (TMZ) for glioblastoma. Following identification of the MTD, adult patients with a histologic diagnosis of glioblastoma were randomized 2:1 between dasatinib given with standard concurrent and adjuvant TMZ, versus placebo with standard concurrent and adjuvant TMZ. Radiation dose was 60 Gy in 30 fractions. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life. Results Thirteen patients were enrolled in the phase I component and established the MTD and phase II dose of 150 mg given daily. A total of 204 patients were enrolled in the phase II component. OS was not different between arms (median OS 15.6 months for dasatinib compared to 19.3 months for placebo, hazard ratio:1.21 favoring placebo, 95% CI: 0.88–1.65, log-rank P-value: .238). Similarly, PFS was not significantly different between the dasatinib and placebo arms. There was a significant increase in anemia, nausea, and creatinine elevation with dasatinib, but significantly more grade 3 lymphopenia with placebo. Conclusions The addition of dasatinib to standard chemoradiation did not improve outcomes for patients with glioblastoma. Clinical Trial Identifier NCT00869401.
The Role of Social Support on Self‐Management of Gestational Diabetes Mellitus: A Qualitative Analysis
Merchant, Tazim , Gomez‐Roas, Maria, Williams, Brittney R., Niznik, Charlotte M. , Feinglass, Joe , Grobman, William A., Yee, Lynn M. , DiTosto, Julia D.

Journal of Midwifery & Women's Health | June 27, 2025 | Volume: 70 | Issue: 5 | Pages: 791-799

10.1111/jmwh.13782 | PMID 40576167 Get It

Introduction Given the rising incidence and importance of treatment adherence for gestational diabetes (GDM), this study aimed to examine patient perspectives on social support's role in gestational diabetes (GDM) management during pregnancy and early postpartum. Methods This is an analysis of qualitative data collected during a feasibility randomized controlled trial of postpartum patient navigation for individuals with GDM. Participants completed semistructured interviews at 4 to 12 weeks postpartum on their experiences with GDM as well as facilitators and barriers to its management, including social support. Data were analyzed using the constant comparative method. Results Of 38 participants, 55% reported a family member or friend with a history of GDM, type 1, or type 2 diabetes mellitus. The analysis identified 4 themes: (1) communal support, (2) indirect GDM support (ie, removing logistical barriers to care), (3) direct GDM support, and (4) barriers of social support (eg, stigma), which impeded disease understanding. Participants identified communal support as a catalyst for lifestyle change and a source for advice and emotional support. Indirect support included transportation, childcare, and work accommodations. Direct support included providing healthy food, giving insulin shots, or providing accountability. Discussion Harnessing social support may be a key strategy to activate and sustain lifestyle and self‐management skills in GDM and should be considered in intervention development.
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium
Boyiadzis, Michael , Wei, Andrew H. , Freeman, Sylvie , Chyla, Brenda , Hersey, Sarah, Patel, Reshma, Maloney, Brian, Zumofen, Marie-Hélène Blanchet , Hoef, Marlies Van, Wulff, Beate, Obourn, Vanessa, Patel, Shalaka, Menezes, Daniel L. , Bengoudifa, Bourras‐Rezki, Dimier, Natalie , Wei, Andrew H , Paiva, Bruno , Kaspers, Gertjan J.L. , Shi, Qian , Prior, Thomas J. , Roboz, Gail J. , Prébet, Thomas

Cancer | June 27, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35960 | PMID 40576165 Get It

AbstractDespite advances in acute myeloid leukemia (AML) treatment, significant unmet medical needs remain. Surrogate end points for overall survival can accelerate the approval of novel therapies. Measurable residual disease (MRD) is a promising surrogate end point candidate, providing a sensitive and quantitative assessment of disease burden. Numerous studies have demonstrated that negative MRD status—across diverse methodologies, assessment timepoints and thresholds, patient subgroups, and clinical settings—independently predicts improved survival. Although MRD can inform therapeutic decisions at the patient level, its formal integration as a primary surrogate end point in regulatory frameworks for clinical trials requires rigorous validation. MRD Partnership and Alliance in AML Clinical Treatment (MPAACT) is a research consortium among industry and academic leaders. MPAACT actively engages with regulatory agencies, health technology assessment bodies, technology vendors, and patient groups to establish a pathway for validating MRD as a surrogate end point in AML clinical trials. For the current article, the authors reviewed the status of MRD assessment, its use in recent clinical trials, current MRD assessment methodologies, standardization, regulatory guidance, statistical approaches, and patient access considerations necessary for MRD to become a surrogate clinical trial end point. The extensive collaboration between MPAACT, global industry, and academic partners—including data sharing and resource integration—underscores the collective commitment to advancing AML therapies. Establishing MRD as a surrogate end point could accelerate the development and approval of innovative treatments, ultimately improving patient outcomes.
Humans with obesity exhibit impaired circulating total, but not free, IGF‐1 response to acute endurance exercise
Freitas, Eduardo D. S. , Roust, Lori R., Filippis, Eleanna De , Brown, Brenna, Katsanos, Christos S. , Brown, Brooke, Katsanos, Christos S , Buras, Matthew

Physiological Reports | June 27, 2025 | Volume: 13 | Issue: 12 | Pages: No page available

10.14814/phy2.70436 | PMID 40574473 Get It

AbstractWe investigated how obesity impacts the response of circulating insulin‐like growth factor‐1 (IGF‐1) to a single bout of endurance exercise in humans with and without obesity. Blood samples were collected before exercise, at 15 and 40 min during a 45‐min cycling session at 65% of heart rate reserve, and 15 min post‐exercise. Serum levels of total IGF‐1, free IGF‐1, IGF binding proteins 1 (IGFBP‐1) and 3 (IGFBP‐3), growth hormone, and insulin were measured. Both total IGF‐1 and IGFBP‐3 serum concentrations increased significantly (p < 0.05) during exercise in the study participants without obesity but not in those with obesity, returning to basal levels immediately after exercise. There was a statistically significant main effect on the growth hormone response, with circulating levels being higher in participants without obesity (p < 0.05). No significant effects were observed for either free IGF‐1 or IGFBP‐1 serum concentrations in response to exercise in either group (p > 0.05). We conclude that humans with obesity have blunted serum total IGF‐1 response during exercise. However, a concurrent attenuation in serum IGFBP‐3 response, which regulates free (i.e., biologically active) IGF‐1 in circulation, results in no change in circulating free IGF‐1 levels during endurance exercise in individuals with obesity.
Artificial Intelligence‐Based Detection of Central Retinal Artery Occlusion Within 4.5 Hours on Standard Fundus Photographs
Gungor, Ayse , Sarbout, Ilias , Gilbert, Aubrey L. , Hamann, Steffen, Lebranchu, Pierre , Gohier, Philippe , Vignal‐Clermont, Catherine, Dumitrascu, Oana M. , Cohen, Salomon Y. , Lagrèze, Wolf A. , Heide, Frank van der, Lamirel, C. , Obadia, Michaël , Miléa, Dan , Gohier, Philippe , Dumitrascu, Oana M , Cohen, Salomon-Yves , Lagrèze, Wolf A , Feltgen, Nicolas , Lamirel, Cédric , Jonas, Jost B , Obadia, Michael , Racoceanu, Daniel , Milea, Dan , Hamann, Steffen , Hobeanu, Cristina , Heide, Frank C. T. van der

Journal of the American Heart Association | June 27, 2025 | Volume: 14 | Issue: 13 | Pages: No page available

10.1161/jaha.124.041441 | PMID 40576025 Get It

Background Prompt diagnosis of acute central retinal artery occlusion (CRAO) is crucial for therapeutic management and stroke prevention. However, most stroke centers lack onsite ophthalmic expertise before considering fibrinolytic treatment. This study aimed to develop, train, and test a deep learning system to detect hyperacute CRAO on retinal fundus photographs within the critical 4.5‐hour treatment window and up to 24 hours after visual loss to aid in secondary stroke prevention. Methods Our retrospective, cross‐sectional study included 1322 color fundus photographs from 771 patients with acute visual loss due to CRAO, central retinal vein occlusion, nonarteritic anterior ischemic optic neuropathy, and healthy controls. Photographs were collected from 9 expert neuro‐ophthalmology centers in 6 countries, including 3 randomized clinical trials. Training included 1039 photographs (517 patients), followed by testing on 2 data sets: (1) hyperacute CRAO (54 photographs, 54 patients) and (2) CRAO within 24 hours after visual loss (110 photographs, 109 patients). Results The deep learning system achieved an area under the receiver operating characteristic curve of 0.96 (95% confidence interval (CI), 0.95–0.98), a sensitivity of 92.6% (95% CI, 87.0–98.0), and a specificity of 85.0% (95% CI, 81.8–92.8) for detecting CRAO at hyperacute stage, with similar results within 24 hours. The deep learning system outperformed stroke neurologists on a subset of hyperacute testing data set (120 photographs, 120 patients). Conclusions A deep learning system can accurately detect hyperacute CRAO on retinal photographs within a time window compatible with urgent fibrinolysis. If further validated, such systems could improve patient selection for fibrinolytic trials and optimize secondary stroke prevention. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06390579.
166 Development of Hypothesised Conceptual Framework for Major Abdominal Surgery
Courtney, Aisling E. , Schatz, Michael, Dorudi, Sina, Courtney, A, Schatz, M, Vindrola‐Padros, Cecilia , Windsor, Alastair C. J. , Moonesinghe, Ramani

British Journal of Surgery | June 27, 2025 | Volume: 112 | Issue: Supplement_10 | Pages: No page available

10.1093/bjs/znaf128.654 Get It

Abstract Aim Major abdominal surgery (MAS) can have a diverse impact on patient’s life, including physical, emotional and socio-economic effects. At present, there is no patient reported outcome (PRO) instrument that was specifically developed for MAS population. The aim of this study was to develop a hypothesised conceptual framework of the key domains that underpin the process of recovery following major abdominal surgery in the adult population. This framework will serve as a foundation for developing a valid PRO instrument for the target population of interest. Method The development of the hypothesised conceptual framework included the following stages: 1) defining major abdominal surgery and verification of its discriminative properties, 2) systematic review of currently available PRO instruments, 3) mapping of the domains within identified PRO instruments to WHO International Classification of Functioning, Disability and Health (ICF) conceptual framework, 4) derivation of the hypothesised conceptual framework by linking of the ICF domains and the health-related quality of life theoretical framework. Results Fourteen PRO instruments were identified by the systematic review. The individual PRO items within each instrument collectively covered 25 ICF domains and 53 sub-domains. A hypothesised conceptual framework was derived based on the “conceptual model of health-related quality of life” and the ICF framework, applied within three principles of exposure, moderating factors and outcomes. Conclusions This study proposed a hypothesised conceptual framework for the development of PRO instruments to evaluate recovery following major abdominal surgery. However, its relevance, content validity and comprehensiveness remain to be examined in future studies.
Association of Covert Cerebrovascular Disease With Falls Requiring Medical Attention
Clancy, Úna , Puttock, Eric J. , Chen, Wansu , Whiteley, William , Vickery, Ellen M. , Leung, Lester Y. , Luetmer, Patrick H. , Kallmes, David F. , Zheng, Chengyi , Kent, David M. , Whiteley, William N , Zheng, Chengyi , Liu, Hongfang , Kent, David M , Luetmer, Patrick H , Fu, Sunyang , Liu, Hongfang

Stroke | June 27, 2025 | Volume: 56 | Issue: 9 | Pages: 2484-2493

10.1161/strokeaha.124.050137 | PMID 40575848 Get It

BACKGROUND: The impact of covert cerebrovascular disease on falls in the general population is not well-known. Here, we determine the time to a first fall following incidentally detected covert cerebrovascular disease during a clinical neuroimaging episode. METHODS: This longitudinal cohort study assessed computed tomography (CT) and magnetic resonance imaging from 2009 to 2019 of patients aged >50 years registered with Kaiser Permanente Southern California which is a healthcare organization combining health plan coverage with coordinated medical services, excluding those with before stroke/dementia. We extracted evidence of incidental covert brain infarcts (CBI) and white matter hyperintensities/hypoattenuation (WMH) from imaging reports using natural language processing. We examined associations of CBI and WMH with falls requiring medical attention, using Cox proportional hazards regression models with adjustment for 12 variables including age, sex, ethnicity multimorbidity, polypharmacy, and incontinence. RESULTS: We assessed 241 050 patients, mean age 64.9 (SD, 10.42) years, 61.3% female, detecting covert cerebrovascular disease in 31.1% over a mean follow-up duration of 3.04 years. A recorded fall occurred in 21.2% (51 239/241 050) during follow-up. On CT, single fall incidence rate/1000 person-years (p-y) was highest in individuals with both CBI and WMH on CT (129.3 falls/1000 p-y [95% CI, 123.4–135.5]), followed by WMH (109.9 falls/1000 p-y [108.0–111.9]). On magnetic resonance imaging, the incidence rate was the highest with both CBI and WMH (76.3 falls/1000 p-y [95% CI, 69.7–83.2]), followed by CBI (71.4 falls/1000 p-y [95% CI, 65.9–77.2]). The adjusted hazard ratio for single index fall in individuals with CBI on CT was 1.13 (95% CI, 1.09–1.17); versus magnetic resonance imaging 1.17 (95% CI, 1.08–1.27). On CT, the risk for single index fall incrementally increased for mild (1.37 [95% CI, 1.32–1.43]), moderate (1.57 [95% CI, 1.48–1.67]), or severe WMH (1.57 [95% CI, 1.45–1.70]). On magnetic resonance imaging, index fall risk similarly increased with increasing WMH severity: mild (1.11 [95% CI, 1.07–1.17]), moderate (1.21 [95% CI, 1.13–1.28]), and severe WMH (1.34 [95% CI, 1.22–1.46]). CONCLUSIONS: In a large population with neuroimaging, CBI and WMH are independently associated with greater risks of an index fall. Increasing severities of WMH are associated incrementally with fall risk across imaging modalities.
921 A Rare Occurrence of Three Primary Malignancies of the Rectum, Kidney and Pancreas in a Same Patient: A Case Report
Akhtar, M A B, Aimon, Sibgha , Syed, Aamir Ali , Kazim, Sayed Moosa, Ahmad, T, Akhtar, M H B

British Journal of Surgery | June 27, 2025 | Volume: 112 | Issue: Supplement_10 | Pages: No page available

10.1093/bjs/znaf128.416 Get It

Abstract Introduction Multiple Primary Malignancies (MPMs) are characterized by the presence of at least two distinct primary malignancies in a patient. The occurrence rate of MPMs is between 1.63% and 10.9% across articles. To our knowledge, this combination of tumours has not been documented in the existing literature. Case: A 44-year-old male, presented with complaints of abdominal pain, chronic constipation, and multiple episodes of bleeding per rectum for one month. Colonoscopy showed proliferative irregular growth at junction of recto-sigmoid colon; Biopsy showed well-differentiated adenocarcinoma. CT scan abdomen and MRI pelvis showed focal eccentric thickening at the rectosigmoid region and enhancing, partly exophytic left renal mass 3.6 x 2.2 x 2.0 cm from the lower pole, another exophytic soft tissue nodule 2.2 x 1.6 x 1.9 cm on inferior surface of body of pancreas. The biopsy of pancreatic mass was neuroendocrine tumour WHO grade 1. KRAS, BRAF, and MSI were negative. A multidisciplinary team discussion was done, and patient underwent laparoscopic-assisted low anterior resection, open left partial nephrectomy, and enucleation of the pancreatic mass in a single setting. The postoperative course remained uneventful. Histopathology showed rectosigmoid tumour: moderately differentiated mucinous adenocarcinoma, 3/19 lymph nodes positive for metastatic carcinoma. Renal tumour Histopathology: 28mm clear cell renal carcinoma. Pancreatic tumour histopathology: solid pseudopapillary neoplasm. All resection margins free of tumour. He received 4 cycles of adjuvant chemotherapy and now he is on surveillance. Conclusions The occurrence of synchronous triple primary malignancies presents a complex clinical challenge and requires meticulous diagnostic evaluation, multidisciplinary collaboration, and personalized treatment strategies.
922 Three Synchronous Squamous Cell Cancers in the Oral Cavity: A Case Report
Akhtar, M A B, Aimon, Sibgha , Hussain, Syed Raza, Naseem, R , Ahmad, T, Faisal, Muhammad , Akhtar, M H B

British Journal of Surgery | June 27, 2025 | Volume: 112 | Issue: Supplement_10 | Pages: No page available

10.1093/bjs/znaf128.417 Get It

Abstract Introduction Synchronous carcinomas are second neoplasms that occur within 6 months of the primary lesion. After this period, they are considered metachronous neoplasms. Literature reported the incidence of synchronous and metachronous carcinoma in the oral cavity from 8% to 21% which is a poor prognostic factor with a subsequently poor overall survival rate. Case Report A 57-year-old male presented with ulcerative lesions in the oral cavity for the last 2 years. He had 25-year history of betel nut chewing. On examination, two ulcerative lesions noted in the oral cavity: on the right upper gingival area measuring approximately 1 x 1 cm with the exposed underlying bone, and another on the left lower gingival area measuring 2 x 2 cm from canine to premolar, subsequently confirmed with MRI. Biopsy confirmed squamous cell carcinoma (SCC). After discussion in the multidisciplinary meeting, he underwent right partial maxillectomy, left marginal mandibulectomy, bilateral neck dissection, and dental extractions, with uneventful post-operative recovery. Histopathology of right partial maxillectomy was moderately differentiated SCC (pT4a), Left marginal mandibulectomy; well-differentiated SCC in the canine area, as well as molar teeth area, and no involved lymph nodes (0/88). All resection margins were free of tumour. Radiotherapy was given to the right maxilla postoperatively. Conclusions To our knowledge, this is the first reported case of triple synchronous SCC oral cavity in our country. Detection of three Synchronous SCCs in the oral cavity follows the concept of field cancerization. A multidisciplinary treatment strategy in a high-volume cancer-dedicated centre is required to aggressively treat such tumours.